CJC-1295 without DAC: Research & Studies

Research Overview#

The research evidence for CJC-1295 without DAC (Modified GRF 1-29) as a standalone compound is limited compared to its DAC-conjugated counterpart. The Modified GRF(1-29) peptide sequence was developed and characterized as part of the CJC-1295 development program by ConjuChem Biotechnologies, but the clinical studies focused on the DAC-conjugated form, which was the intended therapeutic product. Consequently, the evidence base for the non-DAC form relies heavily on: the published CJC-1295 DAC studies that characterize the shared peptide pharmacophore, the broader GHRH analog literature (including sermorelin), and preclinical pharmacology data.

Preclinical Pharmacology#

Modified GRF(1-29) as Part of CJC-1295 Development#

The modified GRF(1-29) sequence used in CJC-1295 (both DAC and non-DAC forms) was developed through systematic structure-activity relationship studies of GHRH analogs. Alba et al. (PMID: 16822960) demonstrated that once-daily CJC-1295 administration normalized growth in GHRH knockout mice, confirming the biological activity of the modified GRF(1-29) peptide sequence in vivo.

The key preclinical findings relevant to the non-DAC form include confirmation that the four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) maintain full GHRH receptor agonist activity equivalent to native GRF(1-29), significant improvement in metabolic stability compared to native GHRH (approximately 3- to 5-fold increase in half-life), and dose-dependent GH release in animal models following subcutaneous administration.

GHRH Analog Class Evidence#

The pharmacology of Modified GRF(1-29) is well-supported by the extensive literature on GHRH analogs as a class. Native GRF(1-29) (sermorelin) was the subject of multiple clinical trials leading to FDA approval for both diagnostic and therapeutic applications. The mechanism of action, receptor pharmacology, and physiological effects of GHRH receptor agonists are thoroughly characterized, and Modified GRF(1-29) shares these fundamental properties.

Studies of sermorelin have demonstrated that GHRH receptor agonists stimulate GH release in a dose-dependent manner, produce discrete GH pulses that mimic physiological GH secretion, augment the nocturnal GH surge when administered before sleep, increase IGF-1 levels with regular administration, and are modulated by somatostatin tone.

Clinical Relevance from CJC-1295 DAC Studies#

While the clinical studies by Teichman et al. (PMID: 16352683) and Ionescu and Frohman specifically evaluated the DAC-conjugated form, they provide important indirect evidence for the pharmacological activity of the Modified GRF(1-29) sequence.

The studies confirmed that the modified GRF(1-29) sequence produces robust GHRH receptor activation in humans, demonstrated dose-dependent GH and IGF-1 responses, and showed that the peptide is well-tolerated with the primary safety concern being injection site reactions. While the pharmacokinetic profile of the DAC form differs dramatically from the non-DAC form, the pharmacodynamic target (GHRH receptor activation leading to GH release) is identical.

Synergy with Ghrelin-Mimetic Peptides#

A significant area of research relevant to Modified GRF(1-29) involves its synergistic interaction with ghrelin-mimetic peptides (GH-releasing peptides or GHRPs). The GHRH pathway and the ghrelin/GHSR pathway represent complementary mechanisms of GH stimulation.

GHRH acts primarily by increasing intracellular cAMP in somatotroph cells, which promotes GH gene transcription and secretory granule exocytosis. Ghrelin-mimetics act through the GHS-R1a receptor to depolarize somatotroph cells via phospholipase C and intracellular calcium mobilization, and also antagonize somatostatin signaling. The combination of both pathways produces synergistic GH release that is substantially greater than the additive effect of either alone.

This synergy has been well-documented in clinical studies using native GHRH combined with ghrelin or synthetic GHRPs. The combination of Modified GRF(1-29) with ipamorelin is one of the most commonly discussed pairings in the research peptide literature, though no formal clinical trials have been published specifically evaluating this combination.

Evidence Quality Assessment#

The evidence for CJC-1295 without DAC as a standalone compound is classified as low quality. This classification reflects the absence of independent clinical trials specifically evaluating Modified GRF(1-29) alone, reliance on extrapolation from DAC-conjugated form studies and the broader GHRH analog class, lack of published human pharmacokinetic data for the non-DAC form specifically, and absence of clinical efficacy data for any therapeutic endpoint.

The evidence is strengthened by the well-characterized pharmacology of the GHRH analog class, the known structure-activity relationships of GHRH receptor agonists, and the clinical data from the CJC-1295 DAC program that validates the biological activity of the shared peptide sequence. However, the absence of independent clinical data means that efficacy and safety claims specific to Modified GRF(1-29) rely on pharmacological reasoning rather than direct clinical evidence.

Future Research Needs#

The most important unmet research needs for CJC-1295 without DAC include independent pharmacokinetic characterization in humans to establish the precise half-life and bioavailability, dose-finding studies to determine optimal dosing frequency and amount, clinical evaluation of the widely discussed combination with ghrelin-mimetic peptides, comparison with other GHRH analogs (sermorelin, tesamorelin) to establish relative potency and clinical utility, and assessment of effects on body composition, physical performance, and quality of life outcomes.

Related Reading#

• CJC-1295 without DAC overview and research guide
• CJC-1295 without DAC dosing protocols
• CJC-1295 without DAC molecular structure